Acquisition of AMAL Therapeutics
Boehringer Ingelheim Acquires AMAL Therapeutics, Significantly Enriching Its Cancer Immunology Portfolio with Novel Cancer Vaccines Platform Acquisition adds key platform supporting Boehringer Ingelheim ’s focus on patients with difficult-to-treat gastrointestinal and lung cancers AMAL ’s first-in-class proprietary KISIMA® platform leverages peptide/protein-based vaccination technology AMAL will remain at the campus of the University of Geneva in Switzerland and operate as a subsidiary within Boehringer Ingelheim
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Cancer Vaccines | Gastroenterology | Mergers and Aquisitions | Research | Switzerland Health | Vaccines